Thursday, January 13, 2022 1:16:14 PM
I would never have invested here had I not known Dr. Dent past some if he can't make a go of HLYK then I won't feel bad. He has a great past and experience and well worth betting on HIM. As for investing in this area I dislike it but I'm betting on Dr. Dent and his experience plus experiences learned. Now George O'Leary not totally convinced if he is on what level of optimistic or a tad BS but again The combination of business experience is good.
Of course I have other thoughts and as I had seen about the so called pending provisional patent... well that is one of my areas of strong interests and we no longer see that so called patent app. There is a time element referencing Provisional patent apps. Look that is for another discussion plus as we know many CEO's need to back up and move in another direction or modify course. No big deal as long as I get answers and beside Dr. Dent with starting NeoGenomic's had modified course several times so no big deal.
You take care and make money on both sides of this stock.
Recent HLYK News
- HealthLynked Announces Fourth Quarter and Full Year 2023 Results Highlighted by 70% Reduction in Net Loss for Q4 • InvestorsHub NewsWire • 04/02/2024 12:00:00 PM
- HealthLynked Announces Exciting New Update with HealthLynked 3.2.0 - Transforming Patient-Care Through Innovation • InvestorsHub NewsWire • 03/26/2024 12:00:00 PM
- HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • InvestorsHub NewsWire • 03/19/2024 12:00:00 PM
- HealthLynked Welcomes David Rosal as New Chief Financial Officer • InvestorsHub NewsWire • 03/13/2024 12:00:00 PM
- HealthLynked Welcomes Garrett Gardi to Its Advisory Board • InvestorsHub NewsWire • 02/28/2024 01:00:00 PM
- HealthLynked and CEO Dr. Michael Dent Featured in Health Documentary "Forever: The End of Aging," Now Available for Streaming • InvestorsHub NewsWire • 01/24/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 08:57:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:05:14 PM
- HealthLynked Unveils Advanced Search Functionality to Improve Patient Care • InvestorsHub NewsWire • 12/13/2023 01:00:00 PM
- HealthLynked Announces Q3 & Year-to-Date 2023 Financial Results, Highlighted by 8% Revenue Growth and Net Income Turnaround • InvestorsHub NewsWire • 11/15/2023 01:00:00 PM
- Introducing the New HealthLynked COVID-19 Tracker: A Comprehensive Tool for the Modern Pandemic Era • InvestorsHub NewsWire • 10/12/2023 12:00:00 PM
- HealthLynked Receives Medicare Shared Savings Net Proceeds from Sale of ACO Health Partners • InvestorsHub NewsWire • 10/09/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 08:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 08:05:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 08:05:28 PM
- HealthLynked Announces Patent Filing for ARI: A Revolutionary AI-Powered Healthcare Interface • InvestorsHub NewsWire • 10/03/2023 12:00:00 PM
- HealthLynked Achieves Key Milestone with Final $300,000 Payment from Sale of ACO Health Partners • InvestorsHub NewsWire • 09/05/2023 12:00:00 PM
- HealthLynked Announces Steady YoY Revenue Increase for Q2 & H1 2023, Highlighting Significant Net Income Boost • InvestorsHub NewsWire • 08/15/2023 12:21:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:12:45 PM
- HealthLynked Corp. Names Wall Street Veteran Mike Paisan to Strategic Investor Relations Role • InvestorsHub NewsWire • 08/01/2023 12:00:00 PM
- HealthLynked Provides Financial Update • InvestorsHub NewsWire • 06/21/2023 12:00:00 PM
- HealthLynked Unveils Major App Update, Enhancing Personalized Healthcare Experience • InvestorsHub NewsWire • 06/06/2023 12:00:00 PM
- HealthLynked Corp. Announces Appointment of Bill Crupi as Regional Manager of Healthcare Services • InvestorsHub NewsWire • 05/23/2023 12:00:00 PM
- Solid Revenue Growth and Earnings Define HealthLynked's Q1 2023 • InvestorsHub NewsWire • 05/16/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM